DISCOUNT ZERTIFIKAT - ASTRAZENECA ADR | Market Closed - Börse Stuttgart 12:57:07 2024-06-25 EDT | ||
| 36.46 EUR | +0.19% |
|
| Current month | +1.67% | ||
| 1 month | +1.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 36.46 | +0.19% |
| 24-06-24 | 36.39 | -0.30% |
| 24-06-21 | 36.5 | +0.25% |
| 24-06-20 | 36.41 | +0.89% |
| 24-06-19 | 36.09 | -0.63% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 12:57 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | ME8MXX |
| ISIN | DE000ME8MXX1 |
| Date issued | 2024-02-13 |
| Maturity | 2024-12-20 (178 Days) |
| Parity | 1 : 1 |
| Emission price | 36.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 36.5 € |
|---|---|
| Lowest since issue | 35.06 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159
USD
Average target price
174.4
USD
Spread / Average Target
+9.68%
- Stock Market
- Certificates
- Certificat
